Genentech has received FDA Priority Review for Gazyva in primary membranous nephropathy, bringing the therapy closer to potentially becoming the first FDA-approved treatment for the rare autoimmune kidney disease.
Key Investor Takeaways
- Genentech (USOTC:RHHBY) received FDA Priority Review for Gazyva® in primary membranous nephropathy (pMN).
- The FDA is expected to make an approval decision by November 2026 following the supplemental Biologics License Application (sBLA).
- Phase III MAJESTY data showed significantly higher complete remission rates for Gazyva compared with tacrolimus after two years.
- If approved, Gazyva would become the first FDA-approved therapy for pMN, a disease with no approved treatments in the U.S. or Europe.
- The regulatory milestone further expands Gazyva’s presence in immune-mediated diseases following its approval for lupus nephritis.
Why RHHBY Stock Is in Focus
Genentech, a member of the Roche Group (USOTC:RHHBY), announced that the U.S. Food and Drug Administration has granted Priority Review to its supplemental Biologics License Application for Gazyva® (obinutuzumab) as a treatment for adults with primary membranous nephropathy.
The review is supported by positive Phase III MAJESTY results, which demonstrated that 36.9% of patients receiving Gazyva achieved complete remission after 104 weeks compared with 5.7% of patients treated with tacrolimus. The study also met key secondary endpoints, including superior overall remission rates, while the safety profile remained consistent with previous experience and no new safety signals were identified.
The FDA had previously granted Breakthrough Therapy Designation for Gazyva in pMN, and a regulatory decision is expected by November 2026. Genentech is also submitting the MAJESTY data to additional global health authorities, including the European Medicines Agency.
Why This Matters for Investors
Priority Review shortens the FDA’s review timeline and reflects the agency’s view that the application could offer a significant improvement in treating a serious condition.
For Roche, a potential approval would expand Gazyva beyond its existing indications in hematological cancers and lupus nephritis into another immune-mediated kidney disease with no currently approved FDA therapies. The opportunity could strengthen the drug’s commercial profile while reinforcing the company’s broader immunology strategy.
The announcement also highlights continued momentum for Gazyva, which has recently received Priority Review in idiopathic nephrotic syndrome and has delivered positive Phase III results across multiple immune-mediated diseases. Continued regulatory success may support further expansion of the franchise.
What to Watch Next
Investors will be watching for the FDA’s decision, expected by November 2026, as well as progress on regulatory reviews in Europe and other international markets.
Additional attention will focus on further clinical and regulatory updates across Roche’s immunology pipeline, including ongoing development of Gazyva in kidney diseases and other immune-mediated conditions.